Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
WAYNE, Pa. - Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company with a market capitalization of $155.49 million currently trading at $1.45, has been added to the broad-market Russell 3000 Index and small-cap Russell 2000 Index following the 2025 Russell US Indexes annual reconstitution, effective at the opening of U.S. equity markets today.
The clinical-stage biopharmaceutical company, which focuses on developing novel product candidates for immuno-inflammatory diseases, will remain in the indexes for one year. According to InvestingPro data, the company maintains a strong balance sheet with more cash than debt and a healthy current ratio of 5.06, though analysts anticipate sales decline in the current year.
The Russell indexes reconstitution process captures the 4,000 largest U.S. stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000 Index automatically includes companies in either the large-cap Russell 1000 Index or small-cap Russell 2000 Index, as well as in appropriate growth and value style indexes.
FTSE Russell, the global index provider, determines membership for its Russell indexes primarily through objective criteria including market capitalization rankings and style attributes.
The Russell indexes serve as benchmarks for investment strategies, with approximately $10.6 trillion in assets benchmarked against them as of June 2024, according to data cited in the company’s press release statement.
Aclaris Therapeutics describes itself as a clinical-stage biopharmaceutical company developing a pipeline of product candidates for patients with immuno-inflammatory diseases who lack satisfactory treatment options. Analyst price targets range from $2 to $16 per share, reflecting diverse views on the company’s potential. For deeper insights into ACRS’s financial health and growth prospects, InvestingPro subscribers can access the comprehensive Pro Research Report, part of the platform’s coverage of over 1,400 US equities.
In other recent news, Aclaris Therapeutics has initiated a Phase 2 trial for its investigational monoclonal antibody, bosakitug, aimed at treating moderate-to-severe atopic dermatitis. The trial follows promising results from a previous Phase 2a study and will involve approximately 90 patients, with results expected in the second half of 2026. H.C. Wainwright has maintained its Buy rating on Aclaris stock, setting a price target of $16, reflecting confidence in bosakitug’s clinical progress. Wedbush has also initiated coverage with an Outperform rating and a price target of $8, highlighting the company’s focus on developing treatments for immunology and inflammation.
Additionally, Aclaris has appointed Dr. Jesse Hall as its new Chief Medical Officer, leveraging his extensive experience to lead the company’s clinical strategy. The company is also progressing its lead small molecule, ATI-2138, with topline results from a Phase 2 trial anticipated in June 2025. In China, Aclaris’ partner is advancing bosakitug in Phase 3 trials for severe asthma and other conditions. Aclaris continues to explore the potential of bosakitug for a variety of diseases, with expectations of significant market impact based on prior successes in the field.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.